Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 3946

1.

Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.

Danowski A, de Azevedo MN, de Souza Papi JA, Petri M.

J Rheumatol. 2009 Jun;36(6):1195-9. doi: 10.3899/jrheum.081194. Epub 2009 May 15.

PMID:
19447935
2.

The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.

Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR.

J Rheumatol. 2001 Dec;28(12):2637-43.

PMID:
11764209
5.

Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome.

Muñoz-Rodríguez FJ, Reverter JC, Font J, Tàssies D, Cervera R, Espinosa G, Carmona F, Balasch J, Ordinas A, Ingelmo M.

Haematologica. 2000 Jun;85(6):632-7.

6.
7.

Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?

Gómez-Puerta JA, Martín H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ, Hughes GR, Khamashta MA.

Medicine (Baltimore). 2005 Jul;84(4):225-30.

8.

[Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].

Sarzi-Puttini P, Atzeni F, Carrabba M.

Minerva Med. 2003 Apr;94(2):63-70. Review. Italian.

PMID:
12858154
9.
11.

Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.

Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM.

Arthritis Rheum. 2004 Aug;50(8):2569-79.

12.

Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis.

Musial J, Swadzba J, Motyl A, Iwaniec T.

J Rheumatol. 2003 Apr;30(4):723-30.

PMID:
12672190
14.
15.
16.

[Prevalence of thrombosis in secondary antiphospholipid-protein syndrome].

Swadźba J, Musiał J, Jankowski M, Grzywacz M, Szczeklik A.

Pol Merkur Lekarski. 1996 Nov;1(5):310-2. Polish.

PMID:
9273202
17.

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.

Calvo-Alén J, Toloza SM, Fernández M, Bastian HM, Fessler BJ, Roseman JM, McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS; LUMINA Study Group.

Arthritis Rheum. 2005 Jul;52(7):2060-8.

19.

Antiphospholipid syndrome and recurrent thrombosis in children.

Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, Revel-Vilk S, Kenet G.

Arthritis Rheum. 2006 Dec 15;55(6):850-5.

20.

Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus.

Woo KS, Kim KE, Kim JM, Han JY, Chung WT, Kim KH.

Korean J Lab Med. 2010 Feb;30(1):38-44. doi: 10.3343/kjlm.2010.30.1.38.

Supplemental Content

Support Center